William G Honer1, Andrea A Jones2, Allen E Thornton3, Alasdair M Barr4, Ric M Procyshyn5, Fidel Vila-Rodriguez6. 1. Professor and Head, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia. 2. Student, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia. 3. Associate Professor, Department of Psychology, Simon Fraser University, Vancouver, British Columbia. 4. Associate Professor, Department of Anesthesia, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia. 5. Clinical Associate Professor, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia. 6. Clinical Assistant Professor, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia.
Abstract
OBJECTIVE: Groups of nonrefractory patients with schizophrenia, taking antipsychotics other than clozapine, show distinct trajectories of treatment response over time. Whether similar patterns of response occur with clozapine-treated patients remains uncertain. METHOD: We used a cluster analysis approach for longitudinal data (k-means longitudinal) to analyze individual patient data from 2 pivotal studies of clozapine, compared with chlorpromazine. Trajectories and symptom severity were examined in a younger, less chronic, mixed-sample (study 16, n=100) and in treatment-refractory (study 30, n=257) patients. RESULTS: Early-good and delayed-partial trajectory groups were observed, with the early-good trajectory group comprised of 73/100 (73.0%) from the mixed patient study, and 147/257 (57.2%) refractory patients. In the mixed patient sample, the distribution of clozapine and chlorpromazine treatments did not differ between the early-good and delayed-partial trajectory groups; in refractory patients proportionately more clozapine treatment was present in the early-good (87/147, 59.2%), compared with the delayed-partial (35/110, 31.8%), trajectory group. In the early-good trajectory group, improvement in mean symptom severity was 63% in mixed-study patients. Clozapine resistance appeared to be present in 10/50 (20.0%) mixed-study patients, and in 35/122 (28.9%) refractory patients. CONCLUSIONS: Early-good and delayed-partial response trajectories are seen in clozapine studies. The advantage of clozapine over chlorpromazine is seen most clearly in previous refractory patients, within the early-good trajectory group. Good and partial or poor responders to clozapine may merit further investigation.
OBJECTIVE: Groups of nonrefractory patients with schizophrenia, taking antipsychotics other than clozapine, show distinct trajectories of treatment response over time. Whether similar patterns of response occur with clozapine-treated patients remains uncertain. METHOD: We used a cluster analysis approach for longitudinal data (k-means longitudinal) to analyze individual patient data from 2 pivotal studies of clozapine, compared with chlorpromazine. Trajectories and symptom severity were examined in a younger, less chronic, mixed-sample (study 16, n=100) and in treatment-refractory (study 30, n=257) patients. RESULTS: Early-good and delayed-partial trajectory groups were observed, with the early-good trajectory group comprised of 73/100 (73.0%) from the mixed patient study, and 147/257 (57.2%) refractory patients. In the mixed patient sample, the distribution of clozapine and chlorpromazine treatments did not differ between the early-good and delayed-partial trajectory groups; in refractory patients proportionately more clozapine treatment was present in the early-good (87/147, 59.2%), compared with the delayed-partial (35/110, 31.8%), trajectory group. In the early-good trajectory group, improvement in mean symptom severity was 63% in mixed-study patients. Clozapine resistance appeared to be present in 10/50 (20.0%) mixed-study patients, and in 35/122 (28.9%) refractory patients. CONCLUSIONS: Early-good and delayed-partial response trajectories are seen in clozapine studies. The advantage of clozapine over chlorpromazine is seen most clearly in previous refractory patients, within the early-good trajectory group. Good and partial or poor responders to clozapine may merit further investigation.
Authors: Virginia Stauffer; Michael Case; Sara Kollack-Walker; Haya Ascher-Svanum; Tamara Ball; Shitij Kapur; Bruce J Kinon Journal: Schizophr Res Date: 2011-04-13 Impact factor: 4.939
Authors: J Claghorn; G Honigfeld; F S Abuzzahab; R Wang; R Steinbook; V Tuason; G Klerman Journal: J Clin Psychopharmacol Date: 1987-12 Impact factor: 3.153
Authors: Jeffrey A Lieberman; Michael Phillips; Hongbin Gu; Scott Stroup; Peiyan Zhang; Lan Kong; Zhongfu Ji; Gary Koch; Robert M Hamer Journal: Neuropsychopharmacology Date: 2003-03-26 Impact factor: 7.853
Authors: M Case; V L Stauffer; H Ascher-Svanum; R Conley; S Kapur; J M Kane; S Kollack-Walker; J Jacob; B J Kinon Journal: Psychol Med Date: 2010-10-07 Impact factor: 7.723
Authors: Jessica W Y Yuen; David D Kim; Ric M Procyshyn; Randall F White; William G Honer; Alasdair M Barr Journal: Front Neurosci Date: 2018-04-04 Impact factor: 4.677
Authors: Jessica W Y Yuen; David D Kim; Ric M Procyshyn; William J Panenka; William G Honer; Alasdair M Barr Journal: Front Endocrinol (Lausanne) Date: 2021-02-25 Impact factor: 5.555